← All trials
NCT05600309
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 14, 2022
- Primary completion
- Aug 15, 2024
- Completion date
- Jul 17, 2025
- First posted
- Oct 31, 2022
- Last posted
- Oct 31, 2022
- Enrollment
- 94
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.